Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure

Yuri M. Lopatin, Giuseppe M C Rosano, Gabriele Fragasso, Gary D. Lopaschuk, Petar M. Seferovic, Luis Henrique W Gowdak, Dragos Vinereanu, Magdy Abdel Hamid, Patrick Jourdain, Piotr Ponikowski

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.

Original languageEnglish
Pages (from-to)909-915
Number of pages7
JournalInternational Journal of Cardiology
Volume203
DOIs
Publication statusPublished - Jan 15 2016

Fingerprint

Trimetazidine
Heart Failure
Energy Metabolism
Fatty Acids
Hemodynamics
Clinical Trials
Guidelines
Glucose
Therapeutics

Keywords

  • Cardiac energy metabolism
  • Heart failure
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. / Lopatin, Yuri M.; Rosano, Giuseppe M C; Fragasso, Gabriele; Lopaschuk, Gary D.; Seferovic, Petar M.; Gowdak, Luis Henrique W; Vinereanu, Dragos; Hamid, Magdy Abdel; Jourdain, Patrick; Ponikowski, Piotr.

In: International Journal of Cardiology, Vol. 203, 15.01.2016, p. 909-915.

Research output: Contribution to journalArticle

Lopatin, YM, Rosano, GMC, Fragasso, G, Lopaschuk, GD, Seferovic, PM, Gowdak, LHW, Vinereanu, D, Hamid, MA, Jourdain, P & Ponikowski, P 2016, 'Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure', International Journal of Cardiology, vol. 203, pp. 909-915. https://doi.org/10.1016/j.ijcard.2015.11.060
Lopatin, Yuri M. ; Rosano, Giuseppe M C ; Fragasso, Gabriele ; Lopaschuk, Gary D. ; Seferovic, Petar M. ; Gowdak, Luis Henrique W ; Vinereanu, Dragos ; Hamid, Magdy Abdel ; Jourdain, Patrick ; Ponikowski, Piotr. / Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. In: International Journal of Cardiology. 2016 ; Vol. 203. pp. 909-915.
@article{5316735dc39e4d67806028d87724f2fb,
title = "Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure",
abstract = "Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.",
keywords = "Cardiac energy metabolism, Heart failure, Trimetazidine",
author = "Lopatin, {Yuri M.} and Rosano, {Giuseppe M C} and Gabriele Fragasso and Lopaschuk, {Gary D.} and Seferovic, {Petar M.} and Gowdak, {Luis Henrique W} and Dragos Vinereanu and Hamid, {Magdy Abdel} and Patrick Jourdain and Piotr Ponikowski",
year = "2016",
month = "1",
day = "15",
doi = "10.1016/j.ijcard.2015.11.060",
language = "English",
volume = "203",
pages = "909--915",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure

AU - Lopatin, Yuri M.

AU - Rosano, Giuseppe M C

AU - Fragasso, Gabriele

AU - Lopaschuk, Gary D.

AU - Seferovic, Petar M.

AU - Gowdak, Luis Henrique W

AU - Vinereanu, Dragos

AU - Hamid, Magdy Abdel

AU - Jourdain, Patrick

AU - Ponikowski, Piotr

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.

AB - Heart failure is a systemic and multiorgan syndrome with metabolic failure as a fundamental mechanism. As a consequence of its impaired metabolism, other processes are activated in the failing heart, further exacerbating the progression of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. Clinical trials have demonstrated that the adjunct of trimetazidine to the conventional medical therapy improves symptoms, cardiac function and prognosis in patients with heart failure without exerting negative hemodynamic effects. This review focuses on the rationale and clinical benefits of trimetazidine by acting on cardiac metabolism in heart failure, and aims to draw attention to the readiness of this agent to be included in all the major guidelines dealing with heart failure.

KW - Cardiac energy metabolism

KW - Heart failure

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=84952803195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952803195&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.11.060

DO - 10.1016/j.ijcard.2015.11.060

M3 - Article

AN - SCOPUS:84952803195

VL - 203

SP - 909

EP - 915

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -